How should I interpret a positive hepatitis B surface antigen (HBsAg) and a positive hepatitis B surface antibody (HBsAb) with a low titer of 14 IU/L?

Concurrent HBsAg and HBsAb Positivity with Low Titer

This pattern represents an unusual but recognized serological profile that most commonly indicates chronic HBV infection with low-level heterotypic antibody formation, not protective immunity—you must confirm active infection with HBV DNA testing and assess for chronic hepatitis B.

Immediate Interpretation

The simultaneous presence of HBsAg and HBsAb with a low titer (14 IU/L) is not a laboratory error and occurs in approximately 24% of HBsAg-positive individuals 1. This pattern does not indicate:

• Recovery from acute infection
• Protective immunity
• Successful vaccination response

What This Pattern Actually Means

Most likely scenario: You are dealing with chronic HBV infection where the patient has developed low-titer heterotypic antibodies (antibodies against a different HBV subtype than the one causing infection). Research shows that 75% of patients with concurrent HBsAg/HBsAb positivity have antibody titers below 10 mIU/ml 1, and your patient's titer of 14 IU/L falls into this low-titer category.

The key mechanism: In chronic infection, patients may produce antibodies against one HBV subtype (e.g., anti-y) while remaining infected with a different subtype (e.g., ad) 1. These heterotypic antibodies are non-neutralizing and provide no clinical protection.

Required Next Steps

Order these tests immediately:

1. HBV DNA (quantitative PCR) - This is the definitive test to confirm active viral replication 2
2. Anti-HBc total - Should be positive in true HBV infection 2
3. HBeAg and anti-HBe - To determine infection phase
4. ALT/AST - To assess hepatic inflammation
5. Repeat HBsAg on different platform - Different assays have varying abilities to detect HBsAg in immune complexes 3

Clinical Significance and Management

This pattern does NOT represent a distinct clinical entity 1. Studies demonstrate that patients with concurrent HBsAg/HBsAb positivity show:

• No differences in risk factors compared to HBsAg-positive/HBsAb-negative patients
• No differences in clinical or histological diagnoses
• No clinical changes when the low-titer antibody appears or disappears 1

Critical caveat: While most cases represent chronic infection with heterotypic antibodies, rare scenarios include:

• Fulminant hepatitis - Concurrent HBsAg/HBsAb was associated with the worst prognosis (6.2% survival) in one study, suggesting rapid immune clearance 4
• Assay interference - Endogenous antibodies or different platform kinetics may produce discrepant results 3
• Immune complex formation - Low levels of either marker may be neutralized and undetected depending on the assay 3

Ruling Out False Positives

To exclude false-positive HBsAg (which can occur with hemodialysis, heterophilic antibodies, or G-CSF use), perform HBsAg neutralization testing with anti-HBs 2. This is the manufacturer-recommended confirmatory test.

Classification Based on HBV DNA Results

Once HBV DNA returns, classify according to the 2025 EASL guidelines 2:

• If HBV DNA >2,000 IU/ml with elevated ALT: Chronic hepatitis B requiring treatment consideration
• If HBV DNA <2,000 IU/ml with normal ALT: Chronic HBV infection (inactive carrier if HBeAg-negative)
• If HBV DNA undetectable: Consider occult HBV infection or resolving infection (though HBsAg positivity makes this unlikely)

Bottom Line

Do not interpret the low-titer HBsAb as protective immunity. The patient almost certainly has chronic HBV infection with non-neutralizing heterotypic antibodies. Confirm with HBV DNA, assess disease activity with ALT and HBeAg status, and manage according to chronic hepatitis B protocols based on the 2025 EASL guidelines 2. The appearance or disappearance of this low-titer antibody has no prognostic significance and should not alter clinical management 1.